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Abstract
Objectives: Metabolic syndrome causes complications like cardiovascular disease and type 2 diabetes
mellitus (T2DM). As metabolic syndrome develops, altered levels of cytokines and microRNAs
(miRNA) are measurable in the circulation. We aimed to construct a panel detecting abnormal levels of
cytokines and miRNAs in patients at risk for metabolic syndrome. Methods: Participants included 54
patients from a Family Medicine Clinic at Marshall University School of Medicine, in groups of: Control,
Obese, and Metabolic Syndrome (MetS). Results: Serum levels of leptin, adiponectin, leptin:
adiponectin ratio, IL-6, six miRNAs (320a, 197-3p, 23-3p, 221-3p, 27a-3p, and 130a-3p), were measured.
Among the three groups, leptin, and leptin: adiponectin ratio, and IL-6 levels were highest in MetS, and
levels in Obese were greater than Control (p>0.05). Adiponectin levels were lower in Obese compared
to Control, but lowest in MetS (p<0.05). MiRNAs levels were lowest in MetS, and levels in Obese were
lower than Control (p>0.05). Conclusion: Our results support the clinical application of biomarkers in
diagnosing early stage MetS, which will enable attenuation of disease progression before onset of
irreversible complications. Since West Virginians are high-risk for developing MetS, our biomarker
panel could reduce the disease burden on our population.
Key words: metabolic syndrome, microRNA, serum biomarkers, West Virginia.

Introduction
Adults in West Virginia have the highest
prevalence of T2DM and hypertension in the US and
are the second most obese state in the country [1]. As
these conditions are associated with MetS, we
conjecture that among adults, West Virginia has a
high prevalence of this disease. MetS manifests as an
aggregate of disorders including hypertension, central
obesity, hyperglycemia, dyslipidemia, and insulin
resistance. The nature of MetS is multi-factorial;
delineating mechanisms of the pathogenesis is a

complex and unfinished task [2]. As a chronic
disorder, MetS progresses discretely until potentially
devastating complications arise [3-6]. Medical
expenses of patients with MetS are higher than those
without MetS with a 20% increase in cost for every
additional component of MetS [7, 8]. Due to the
indolent nature of MetS, the financial burden and the
healthcare disparities, populations like those in West
Virginia suffer a significant disease burden. Along
with comprehensive community based programs for
http://www.medsci.org

544

Int. J. Med. Sci. 2017, Vol. 14
disease management, prevention, and early
intervention are vital components for combatting this
disease [9]. Since this profoundly impacts our
population, it is vital to determine a method that
reduces MetS and associated complications [2].
From a literature review, we extrapolated
biomarkers suitable for inclusion in a panel for MetS
detection [2]. Leptin is found at increased levels in
patients with MetS and specifically with abdominal
obesity, and insulin resistance [10] [11-13]. Increased
adiponectin levels improve insulin sensitivity,
vasodilation, and lipid oxidation, while protecting
against atherogenesis [14-16]. Levels are low in people
at risk for developing T2DM, hypertension, and
obesity [17, 18]. The leptin to adiponectin (LAR) ratio
overcomes the limit that exists in the values of
adiponectin and leptin during the fasting versus
postprandial state [19]. MetS induces an inflammatory
state, increasing levels of the pro-inflammatory
cytokines, such as IL-6. IL-6 levels correlate with
elements of MetS, MetS alone, and the severity of
MetS [20-22].
MiRNAs are small single-stranded RNA
molecules that alter gene expression by preventing
translation; this happens after transcription coding
messenger RNA is modified or silenced by miRNA
[23, 24]. MiRNAs are transported into the circulation
and function in various pathways such as metabolism
[23, 25, 26]. A dysregulated metabolic process is
caused by abnormally functioning miRNAs and is
implicated in the development of CVD, MetS, and
T2DM [23]. The use of miRNAs for clinical testing of
disease is applicable since numerous studies conclude
that a statistically significant variance exists between
the control groups and people with metabolic disease.
As reported in the literature, we selected miRNAs that
correlated with components of MetS for the panel in
our study. MiRNAs: 320a, 197-3p, 23-3p, 221-3p,
27a-3p, and 130a-3p exhibit altered levels correlating
with pathophysiological components of MetS [24, 25,
27-32]. Levels of miR-320a, miR-27a-3p, miR-130a-3p,
miR-23-a and miR-221 vary in the circulation of
patients with MetS [25, 30, 33]. Studies revealed that
levels of miR-130a-3p, miR-221, miR-197, and
miR-23-a, corresponded to states of obesity [25, 30,
33]. Circulating levels of miR-23-a, miR-197,
miR-27a-3p, and miR-130a-3p vary in the circulation
of patients with hypertension [25, 30, 33]. Previous
studies demonstrated the existence of a relationship
between varied blood glucose levels and miR-320a
miR-197 [25, 30, 33]. In patients with known insulin
resistance miR-130a-3p and miR-320a tend to exhibit
variation in circulating levels [24, 25, 30]. MiRNAs
appear to be useful for pre-clinical diagnosis, since
they are more sensitive and specific for early

diagnosis, risk assessment and monitoring disease
progression [24]. MiRNAs exhibit remarkable stability
under harsh conditions such as: pH, temperature,
storage, and multiple freeze-thaw cycles [24, 31].
A panel of biomarkers used to diagnose MetS in
the early stage, allows for prevention of debilitating
conditions that accompany MetS [34]. In this study we
measured serum biomarkers and miRNA associated
with MetS. We studied a group of adult females in
West Virginia with normal BMI, obesity and a
diagnosis of MetS. Our objectives for this study
included: detecting circulating levels of biomarkers
associated with MetS in patients at risk for developing
this disease and developing a biomarker panel
providing early detection, risk assessment and
monitoring of MetS. A biomarker panel for MetS, with
the potential for prevention and early intervention,
could greatly impact populations at high risk for the
disease, such as the people of West Virginia [2].

Material and Methods
Patients
A total of 54 adult females, visiting the Family
Medicine Clinic at Marshall University School of
Medicine, were enrolled in this study and each signed
an informed consent. The patients were grouped into
categories based on BMI and MetS diagnosis: 1.
Control group with a BMI <30; 2. Obese group with a
BMI ≥30 and no clinical diagnosis of MetS, and 3.
MetS, patients carrying a clinical diagnosis of MetS.
Patients with malignancy, trauma or age under 18 or
over 45, were excluded from this study. Trained
personnel followed a standard protocol to measure
the height, weight, waist circumference (midway
from the lowest rib to the iliac crest to the nearest 0.1
cm), and blood pressure of each patient. BMI was
calculated for the individual by dividing weight (kg)
by the square of height (m). The Ethics Committee of
the Cabell Huntington Hospital, West Virginia
approved this study.

Blood Samples
Study patients had venous blood drawn from an
antecubital vein in EDTA tubes after fasting for at
least 8 hours. The blood obtained was intended to
acquire levels of inflammatory cytokines, miRNA,
blood glucose levels, and lipid panels. Blood samples
were processed by spinning blood at 3000 rpm for 10
minutes at 4ºC. Serum for cytokine and miRNA
analysis was frozen at -80ºC prior to analysis. The
laboratory, at Cabell-Huntington Hospital, analyzed
blood for glucose levels and lipid panels; these values
were obtained from the patient chart.

http://www.medsci.org
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Biomarker Quantification
Enzyme-linked immunosorbent assays (ELISA)
were used to determine levels of leptin (EMD
Millipore Corporation, Billerica, MA), HMW
adiponectin (Abcam plc, Cambridge, UK), IL-6 (R&D
Systems, Inc., Minneapolis, MN). All protocols
provided by the manufacturer were followed for each
ELISA kit.

Extraction of miRNA
We performed RNA extraction using the
miRNeasy SerumPlasma Kit (Qiagen, Hilden,
Germany)
according
to
the
manufacturer’s
instructions. 1 ml of QIAzol reagent was added to 200
ml of serum sample. The samples were vortexed in a
tube, followed by the addition of 200 µl of chloroform.
After mixing vigorously, the samples were then
centrifuged at 12,000 g for 15 min at 4°C. The upper
aqueous phase was transferred to a new collection
tube, and 900 µl of absolute ethanol was added. The
samples were then applied directly to columns and
washed. Total RNA was eluted in 14 µl of
nuclease-free H2O. The quality and quantity of RNA
were evaluated by 260:280 ratio using NanoDrop
analyzer (Thermo Scientific). For RT reaction, we used
the miRCURY LNA Universal RT microRNA PCR Kit
(Exiqon, Vedbaek, Denmark). Each RT reaction used
50 ng of total RNA. Total RNA was combined with 4
µl of 5x reaction buffer, 9 µl of nuclease-free water, 2
µl of enzyme mix and 0.5 µl of synthetic spike-in to a
final volume of 20 µl. The RT-PCR was set as follows
incubated at 42°C for 1 h, heat-inactivated at 95°C for
5 min and immediately cooled to 4°C. The expression
levels of miRNA in serum samples were studied with
a SYBR-based quantitative PCR using a miRNA
specific primer and ExiLENT SYBR Green Master mix
(Exiqon). To normalize the miRNA expression the
internal control, the synthetic spike-in, was used. The
expression levels of miRNA were then assessed by
real-time quantitative PCR (qRT-PCR) according to
the manufacturer’s instructions. A 4 µl aliquot of 40x
diluted cDNA template was combined with 5 µl of
SYBR green master mix and 1 µl of PCR primer mix to
a final volume of 10 µl. Two technical replicates per
sample were used for qRT-PCR amplification run on a
7500 Fast Real-Time PCR Systems (Applied

Biosystems). The sequence of miRNAs are listed
below.
Table A: Sequence of miRNAs.
miRNA
hsa-miR-320a
hsa-miR-197-3p
hsa-miR-23-3p
hsa-miR-221-3p
hsa-miR-27a-3p
hsa-miR-130a-3p

sequence
AAAAGCUGGGUUGAGAGGGCGA
UUCACCACCUUCUCCACCCAGC
AUCACAUUGCCAGGGAUUUCC
AGCUACAUUGUCUGCUGGGUUUC
UUCACAGUGGCUAAGUUCCGC
CAGUGCAAUGUUAAAAGGGCAU

Statistical Analysis
Data analysis was performed using GraphPad
Prism 4.0. Within each of the three patient categories,
Bartlett’s test was applied for each biomarker to
guarantee equal variance. For each biomarker,
differences of statistical significance were identified in
the average serum levels using ANOVA. Specification
of the patient groups that showed statistically
significant variances for the biomarker measured was
achieved using the Turkey post-hoc test.

Results
In the clinic, 54 patients were recruited into the
study and placed in one of three groups: individuals
with a normal BMI and no MetS (n=24), obese
individuals with no clinical diagnosis of MetS (n=17)
and obese individuals with a clinical diagnosis of
MetS (n=16). All participants were adults and female.
There was no difference between the groups in the
mean age ratio. Adult females with MetS showed
significant differences in clinical markers compared to
those without MetS. Additionally, obese adult females
and adult females with MetS showed significant
differences in the cytokines and miRNA associated
with MetS compared to the Control patients.

Clincial markers of MetS
As shown in table 1, Systolic blood pressure was
significantly elevated in Obese and MetS patients
compared to Control (p<0.01). Fasting blood glucose
and triglycerides were significantly elevated in
patients with MetS only (p<0.01). HDL was decreased
in the MetS group (p<0.01). These are the variables
included in the IDF definition of MetS and are used to
make the clinical diagnosis of MetS [5].

Table 1. Patient Demographic and Clinical Profile.
Groups
Control
Obese
MetS

Number of Patients
24
17
16

Age (yrs.)
33.29 (±1.4)
38.5 (±2.3)
38.5 (±2.2)

BMI (kg/m2)
23.30 (±0.7)
43.57 (±2.95)
48.5 (±3.73)

FBS (mg/dL)
88.05 (±1.5)
87.83 (±2.2)
111.62 (±7.2)* #

SBP (mmHg)
111.73 (±2.4)
130.58 (±4.2)*
136.3 (±4.9)*

DBP(mmHg)
69.86 (±2.1)
77.76 (±3.1)
85.75 (±1.5)*

TG (mg/dL)
94 (±7.2)
81.5 (±7.2)
141.86 (±9.4)* #

HDL (mg/dL)
62.84 (±2.9)
66.67 (±2.9)
43.4 (±1.8)* #

Values represent means ± SEM. *p<0.01 vs. Control, # p<0.01 vs. Obese. Body mass index (BMI), Fasting blood sugar (FBS), Systolic blood pressure (SBP), Diastolic blood
pressure (DBP), Triglyceride (TG), High density lipoprotein (HDL) in Control, Obese and MetS patients.
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Serum cytokine biomarkers
Adipokines, leptin and adiponectin, are
bioactive substances released by adipocytes that
control appetite, promote effective glucose use, and
enhance insulin sensitivity. As adipocytes accumulate
in obesity, these cytokines become dysregulated
initiating MetS [2]. Compared to the Control group,
leptin was significantly elevated in the Obese group
and even more so in the MetS group (p<0.05), figure 1
(A). Adiponectin was significantly decreased in the
Obese group and more so in the MetS group
compared to the Control (p<0.05) figure 1 (B). Obese
patients showed significantly higher LAR to Control
and LAR in the MetS group was the highest of the
three groups (p<0.05) figure 1 (C). The dysregulated
adipokines of MetS induce an inflammatory response
and release of pro-inflammatory cytokines such as
IL-6 into the circulation [2]. Our results show that IL-6
was significantly highest in the MetS group and the
Obese group had higher levels of IL-6 compared to
Control (p<0.05) figure 1 (D).

a similar statistically significant pattern. The
following miRNAs: 320a, 197-3p, 23-3p, 221-3p,
27a-3p, and 130a-3p exhibit dysregulated activity in
the setting of MetS resulting in variable levels [24, 25,
27-32]. Each miRNA studied showed greatest
decrease in the circulation of the MetS group but was
also decreased in the obese group compared to the
Control (p<0.05); results depicted in figure 2 and 3
(A-C respectively).

Comparing clinical markers and serum
biomarkers

Mean clinical values, mean values of serum
cytokine biomarkers and serum miRNAs were
compared in table 2. Among the Obese group, mean
values of systolic blood pressure, leptin, LAR, IL-6
were significantly elevated compared to Control
(p<0.01). Levels of adiponectin and miRNAs: 320a,
197-3p, 23-3p, 27a-3p, 130a-3p, were significantly
decreased in the Obese group when compared to
Control (p<0.01). Among the MetS group, mean
values of fasting blood sugar, systolic and diastolic
blood pressure, triglycerides, leptin, LAR, IL-6 were
Circulating miRNA biomarkers
significantly elevated compared to Control (p<0.01).
Altered function and variable circulating levels
Levels of HDL, adiponectin, and miRNAs: 320a,
of miRNAs, regulators of genetic expression, correlate
197-3p, 23-3p, 221-3p, 27a-3p, 130a-3p, were
with MetS and its components [25]. All six miRNAs
significantly decreased in the MetS group when
analyzed in the circulation of these patients followed
compared to Control (p<0.01). Among the MetS
group, mean values of
fasting
blood
sugar,
triglycerides, leptin, LAR,
IL-6 were significantly
elevated
compared
to
Obese (p<0.01). Levels of
HDL and miRNAs: 320a,
197-3p,
23-3p,
27a-3p,
130a-3p, were significantly
decreased in the MetS
group when compared to
Obese
(p<0.01).
The
correlation between the
mean values of serum
cytokine biomarkers and
serum miRNA from all
three groups were depicted
in scatterplots in figures
4-6. Adiponectin, leptin,
and IL-6 values were
compared to each miRNA
individually in figures 4
(A-F), 5 (A-F), and 6 (A-F)
Figure 1. Cytokines. Assay of serum concentrations of (A) Leptin, (B) Adiponectin, (C) Leptin: Adiponectin Ratio, (D)
respectively.
IL-6 in Control (n=24), Obese (n=17), and MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs.
Control; # p<0.01 vs. Obese.
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Figure 2. Circulating miRNAs. Assay of serum concentrations of circulating (A) miR-320a, (B) miR-197-3p, and (C) miR-23-3p in Control (n=24), Obese (n=17), and
MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. Control; # p<0.01 vs. Obese.

Figure 3. Circulating miRNAs. Assay of serum concentrations of circulating (A) miR-221-3p, (B) miR-27a-3p, and (C) miR-130a-3p Control (n=24), Obese (n=17),
and MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. Control; # p<0.01 vs. Obese.
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Int. J. Med. Sci. 2017, Vol. 14

548

Table 2. Comparing clincal markers and serum biomarkers and miRNAs

Comparing mean clinical values associated with metabolic syndrome with mean serum biomarkers and serum miRNAs mean values from three groups: Control (n=24),
Obese (n=17), and MetS (n=16), patient groups. Values represent means ± SEM. *p<0.01 vs. Control, # p<0.01 vs. Obese. Body mass index (BMI), Fasting blood sugar (FBS),
Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Triglyceride (TG), High density lipoprotein (HDL) in Control, Obese, and MetS patients.

Figure 4. Correlation of adiponectin with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation
to miR320 (r=0.55; p<0.05), (B) miR197 (r=0.477; p<0.05) (C) miR23a (r=0.51; p<0.05), (D) miR221 (r=0.46; p<0.05)), (E) miR2713p (r=0.54; p<0.01)), and (F)
miR130a3p (r=0.54; p<0.01)).
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Figure 5. Correlation of leptin with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation to
miR320 (r= -0.86; p<0.01), (B) miR197 (r= -0.79; p<0.01) (C) miR23a (r= -0.79; p<0.01), (D) miR221 (r= -0.54; p<0.01)), (E) miR2713p (r= -0.80; p<0.01)), and (F)
miR130a3p (r= -0.79; p<0.01)).

Figure 6. Correlation of IL-6 with miRNAs; mean values from three groups. Control (n=24), Obese (n=17), and MetS (n=16), patient groups. (A) Correlation to
miR320 (r= -0.71; p<0.01), (B) miR197 (r= -0.61; p<0.01) (C) miR23a (r= -0.70; p<0.01), (D) miR221 (r= -0.59; p<0.01)), (E) miR2713p (r= -0.63; p<0.01)), and (F)
miR130a3p (r= -0.60; p<0.01)).
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Figure 7. In this scheme, the progression of MetS is represented. Once the patient is at risk for MetS, pathophysiological changes alter biomarker levels. If a
biomarker profile permits the diagnosis of MetS in the early stage, then disease progression is impeded prior to the onset of irreversible sequel.

Discussion
The results of our study indicate that a panel of
biomarkers has a significant role in the detection of
early stage MetS, before irreversible complications
develop. Our results demonstrate statistically
significant circulating levels of cytokines and miRNA
associated with MetS displayed in a profile unique to
each group of our population. This shows that
pathologic changes occurring at the cellular level are
translated through our data prior to perceptible
clinical markers. This approach improves the
recognition and diagnosis of MetS and is summarized
in the schematic diagram, figure 7. Furthermore, a
pattern of disease progression is evident in the
biomarker profile. These trends are unique to the
population of adult West Virginian females with
obesity and MetS in our study. Our study indicated
altered levels of cytokines (leptin, adiponectin and
IL-6) and decreased levels of miRNAs (320-a, 197-3p,
23-3p, 221-3p, 27a-3p and 130a3p) appear in the
circulation of patients indicating early stage MetS.
MetS is a multifactorial disease, and delineating
pathogenic mechanisms is complex; however, insulin
resistance and central obesity are instrumental in
disease
development.
Current
strategies
of
diagnosing MetS rely on lipid, insulin and glucose

levels, blood pressure and BMI or waist
measurements [5]. Criteria that meet diagnosis of
MetS indicate pathologic conditions of these levels
and measurements. Once these indicators coincide
with the diagnosis of MetS, complications develop
with an increased risk of permanent disability and
mortality, emphasizing the need to diagnose MetS in
the early stage.
Dysregulation of leptin and adiponectin
contribute to the progression of MetS. Deleterious
effects of high levels of leptin, as in MetS, include:
angiogenesis, hypertension, atherosclerosis and
myocardial remodeling [14, 35, 36]. Leptin levels were
highest in the MetS group and elevated in the Obese
group compared to Control in our results. Elevated
levels of circulating leptin indicate the metabolic
changes are progressing to MetS. Protective
properties of adiponectin fade at lower levels and are
negatively correlated with glucose, insulin, and
triglyceride levels, as well as adipose tissue
accumulation and elevated blood pressure [12, 35, 37].
Consistent with previous studies, our data identified
decreased levels of adiponectin in the MetS and Obese
groups, indicating that disease progression of MetS
occurs before recognition of current clinical measures.
The inflammatory state of MetS causes the
release of the cytokine IL-6. In obesity, reactive
http://www.medsci.org
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oxygen species are formed from high levels of lipid
oxidation, which precipitates systemic stress and the
release of inflammatory cytokines [38]. In this
dysregulated environment, IL-6 activates receptors to
induce insulin resistance. IL-6 damages vascular
endothelium to initiate atherosclerotic plaque
formation [39-41]. Circulating levels of IL-6 correlate
with the severity of MetS [20-22]. In our data, IL-6 was
increased in the Obese and even more so in the MetS
group establishing congruity between elevation of
this biomarker and formation of an early diagnosis of
MetS.
From the literature we chose miRNAs: 320a,
197-3p, 23-3p, 221-3p, 27a-3p, and 130a-3p to
investigate in our population [24, 25, 27-32]. This
group was selected, based on previous studies, since
they all detect MetS in the early stage. All six miRNAs
were significantly decreased in the circulation of the
Obese group and even more so in the MetS group.
This pattern indicates the value of including these
miRNAs in a biomarker panel for MetS in our
population.
Levels of circulating miRNA are not uniformly
expressed between studies, which may reflect
intergroup variance. Expression of miR-320a is
dysregulated within insulin-resistant adipocytes [25,
30, 33]. A study of patients with T2DM in the United
Kingdom found levels of circulating miR-320a
decreased in of patients with T2DM [32]. Conversely,
a study from Singapore detected a positive correlation
between circulating miR-320a and fasting blood
glucose levels, up regulation of miR-320a levels in
patients with MetS and T2DM was also observed [25].
In a group of Asian Indians, miR-197 negatively
correlated with the level of glycemic impairment and
also decreased in T2DM and among a different Asian
population, miR-197 was down regulated in MetS [29,
32]. However, other studies reveal that circulating
miR-197 levels are increased in MetS, decreased in
hypertension and positively correlated with elevated
BMI [25, 30, 33]. MiR-23-a is associated with several
metabolic pathways such as: glucose homeostasis,
insulin secretion, lipid and carbohydrate metabolism
[31]. In a study of adult Chinese females, the levels
were distinct in patients with pre-diabetes versus
T2DM [31]. Circulating amounts of miR-23a vary, but
are positively correlated with BMI, increased in MetS,
decreased in T2DM and hypertension [25]. MiR-221
displays decreased expression in obesity [24, 33].
However, among a group of Chinese women,
circulating levels of miR-221-3p were higher in
non-obese with MetS [27]. Physical activity and
bariatric surgery increased the expression of
miR-221-3p; known to be down regulated in the
circulation and adipocytes of obese individuals [30,

42]. MiR-27a-3p is a regulator in adipogenic pathways
and studies report that levels are increased MetS and
in T2DM, but decreased in hypertension [25, 27, 33].
Circulating miR-130a-3p exhibited variability as
decreased levels in obesity, T2DM and cardiovascular
disease, while levels were increased in MetS,
hypertension and insulin resistance; diets low in
glycemic index, decreases the expression of
circulating miR-130a-3p [24, 25, 30].
MiRNAs are targets for therapeutic strategies
since they are key regulators in various pathways of
disease. Monitoring miRNA in the circulation could
provide: evaluation of disease progression, risk,
susceptibility, treatment while offering a confirmation
of a preclinical diagnosis [24]. One study examined
intergroup differences of circulating miRNAs
associated with T2DM. Levels of MiR-144 were
significantly high in a Swedish population with
T2DM but not in Iraqis; ethnic variation could explain
this difference [28]. Levels of miRNA signal variation
between the sexes may account for the sex differences
found in the cardiovascular sequela of MetS [27].
Whether this difference results from diversity of
genetics, environment, diet or lifestyle remains to be
determined. The use of miRNAs in clinical testing of
disease is applicable as numerous studies find that
they exhibit a statistically significant variance
between healthy and metabolic diseased individuals.
MiRNAs appear to be a useful addition to a panel of
biomarkers for pre-clinical diagnosis, risk assessment,
and monitoring progression of MetS [24].
Biomarkers, like cytokines and miRNA, allow
clinicians to diagnose, manage and stratify a patient’s
risk for disease states as depicted in figure 7
(schematic). Clinical application of a panel for MetS
could prompt early detection and intervention before
development of systemic complications. Since
biomarkers have roles in various pathways, a panel of
several biomarkers increases the specificity and
sensitivity of disease detection. The panel could
profoundly impact populations affected by this
disease, such as the people of West Virginia.

Conclusion
MetS places a major disease burden on the
population of West Virginia. Although further
research is necessary to determine the predictive
value of the considered serum biomarkers and
miRNAs in regards to MetS, our results demonstrate
that the biomarkers and miRNAs studied all showed
a significant correlation to the disease states of MetS
and obesity in a population of West Virginia females.
Our formulated biomarker and miRNA panel has
significant potential for detection of MetS and
attenuation of disease progression prior to onset of
http://www.medsci.org
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irreversible complications. In turn, this could reduce
the disease burden of MetS on our West Virginia
population.
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